DOSE-DEPENDENT CYTOTOXIC AND MUTAGENIC EFFECTS OF ANTINEOPLASTIC ALKYLATING-AGENTS ON HUMAN LYMPHOBLASTOID-CELLS

被引:18
作者
SANDERSON, BJS [1 ]
JOHNSON, KJ [1 ]
HENNER, WD [1 ]
机构
[1] OREGON HLTH SCI UNIV,DIV HEMATOL & MED ONCOL,L-586,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201
关键词
MAMMALIAN; MUTATION; TOXICITY; ALKYLATING; NITROGEN MUSTARD;
D O I
10.1002/em.2850170404
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
The alkylating agents in clinical use as antineoplastics are strongly implicated as human carcinogens on the basis of animal studies and human epidemiologic studies. However, there is little quantitative information on the extent to which exposure to these drugs is mutagenic for normal (non-malignant) cells and the extent to which such mutagenicity correlates with cytotoxicity of these agents. Human lymphoblastoid cells (WIL2-NS) were exposed to graded doses of eight antineoplastic alkylating agents. Cell killing and mutation induction at the hypoxanthine-guanine phosphoribosyltransferase (HPRT) locus were measured by cloning in microplates in the presence and absence of 6-thioguanine. Dose-dependent decreases in survival were used to calculate IC50s for each of the drugs tested. The IC50s, for 1 hr exposure, ranged from 4 x 10(-7) M for nitrogen mustard to 5 x 10(-4) M for busulfan. The eight drugs tested each induced detectable increases in the frequency of mutant cells. The mutagenicity of these agents is correlated strongly with cytotoxicity. However, at equitoxic doses (IC50), the frequency of induced mutants ranged from approximately 3 x 10(-6) for 1,3-bis(2-chlorethyl)-1-nitrosourea (BCNU) to 2 x 10(-5) for busulfan and cisplatin. These results quantitate the dose-dependent cytotoxic and mutagenic effects of these bifunctional alkylating agents on human cells. All are cytotoxic and mutagenic, although their mutagenic efficiency varies.
引用
收藏
页码:238 / 243
页数:6
相关论文
共 38 条
[1]   MUTATION AT THE HPRT LOCUS - WORKSHOP ON MUTATION AT THE HPRT LOCUS, STOCKHOLM, MAY 26-28, 1988 [J].
ALBERTINI, RJ ;
GENNETT, IN ;
LAMBERT, B ;
THILLY, WG ;
VRIELING, H .
MUTATION RESEARCH, 1989, 216 (01) :65-88
[2]   ELEVATED FREQUENCIES OF 6-THIOGUANINE-RESISTANT LYMPHOCYTES IN MULTIPLE-SCLEROSIS PATIENTS TREATED WITH CYCLOPHOSPHAMIDE - A PROSPECTIVE-STUDY [J].
AMMENHEUSER, MM ;
WARD, JB ;
WHORTON, EB ;
KILLIAN, JM ;
LEGATOR, MS .
MUTATION RESEARCH, 1988, 204 (03) :509-520
[3]  
BENEDICT WF, 1977, CANCER RES, V37, P2209
[4]   LEUKEMIA AND PRELEUKEMIA AFTER ADJUVANT TREATMENT OF GASTROINTESTINAL CANCER WITH SEMUSTINE (METHYL-CCNU) [J].
BOICE, JD ;
GREENE, MH ;
KILLEN, JY ;
ELLENBERG, SS ;
KEEHN, RJ ;
MCFADDEN, E ;
CHEN, TT ;
FRAUMENI, JF .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (18) :1079-1084
[5]   HPRT LOCUS [J].
CASKEY, CT ;
KRUH, GD .
CELL, 1979, 16 (01) :1-9
[6]  
COLTMAN CA, 1982, CANCER TREAT REP, V66, P1023
[7]   CHROMOSOME DAMAGE DURING NITROGEN MUSTARD THERAPY - A CASE REPORT [J].
CONEN, PE ;
LANSKY, GS .
BRITISH MEDICAL JOURNAL, 1961, 2 (525) :1055-&
[8]  
Crespi C. L., 1985, PROGR MUTATION RES, V5, P497
[9]   THE INDUCTION OF ANEUPLOIDY BY NITROGEN-MUSTARD IN A HUMAN-LYMPHOBLASTOID CELL-LINE [J].
CRESPI, CL ;
SEIXAS, GM ;
PENMAN, BW .
MUTATION RESEARCH, 1987, 190 (01) :69-76
[10]  
CURTIS RE, 1990, CANCER RES, V50, P2741